tumour-infiltrating gr-+ myeloid cells antagonize senescence cancer
aberrant activation oncogenes loss tumour suppressor genes opposes malignant transformation triggering stable arrest cell growth termed cellular senescence- process finely tuned cell-autonomous non-cell-autonomous mechanisms regulate entry tumour cells senescence- whether tumour-infiltrating immune cells can oppose senescence unknown show onset senescence pten null prostate tumours inmice massively infiltrated population cd11b+gr-+ myeloid cells protect fraction proliferating tumour cells senescence thus sustaining tumour growth mechanistically found gr-+ cells antagonize senescence paracrine manner interfering senescence-associated secretory phenotype tumour secretion interleukin receptor antagonist il-1ra strikingly pten-loss-induced cellular senescence enhanced vivo il1ra knockout myeloid cells adoptively transferred pten null mice therapeutically docetaxel-induced senescence efficacy higher pten null tumours percentage tumour-infiltrating cd11b+gr-+myeloid cells reduced using antagonist cxc chemokine receptor cxcr2 taken together findings identify novel non-cell-autonomous network established innate immunity controls senescence evasion chemoresistance targeting network provides novel opportunities cancer therapy
